135 related articles for article (PubMed ID: 15848571)
1. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation.
Tellis V; Schechner R; Mallis M; Rosegreen S; Glicklich D; Moore N; Greenstein S
Transplant Proc; 2005 Mar; 37(2):906-8. PubMed ID: 15848571
[TBL] [Abstract][Full Text] [Related]
2. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation.
Walker JK; Alloway RR; Roy-Chaudhury P; Mogilishetty G; Cardi MA; Weimert NA; Rike AH; First MR; Woodle ES
Transplantation; 2009 Feb; 87(3):408-14. PubMed ID: 19202447
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
van Hooff JP; Squifflet JP; Wlodarczyk Z; Vanrenterghem Y; Paczek L
Transplantation; 2003 Jun; 75(12):1934-9. PubMed ID: 12829890
[TBL] [Abstract][Full Text] [Related]
4. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration.
Andrés A; Budde K; Clavien PA; Becker T; Kessler M; Pisarski P; Fornara P; Burmeister D; Hené RJ; Cassuto-Viguier E;
Transplantation; 2009 Nov; 88(9):1101-8. PubMed ID: 19898206
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
7. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
[TBL] [Abstract][Full Text] [Related]
8. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
Heilman RL; Mazur MJ; Reddy KS; Moss A; Post D; Mulligan D
Transplant Proc; 2005 May; 37(4):1785-8. PubMed ID: 15919466
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
[TBL] [Abstract][Full Text] [Related]
10. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
Osuna A; Gentil MA; Capdevila L; Cantarell C; Mazuecos A; Pereira P; Rodríguez-Algarra G; González-Molina M;
Transplant Proc; 2005 Apr; 37(3):1438-40. PubMed ID: 15866630
[TBL] [Abstract][Full Text] [Related]
11. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.
Chan L; Greenstein S; Hardy MA; Hartmann E; Bunnapradist S; Cibrik D; Shaw LM; Munir L; Ulbricht B; Cooper M;
Transplantation; 2008 Mar; 85(6):821-6. PubMed ID: 18360262
[TBL] [Abstract][Full Text] [Related]
13. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
Liu KL; Chu SH; Chiang YJ; Wu CT; Chen Y
Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
[TBL] [Abstract][Full Text] [Related]
15. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
Videla CO
Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper).
Trotter JF; Wachs M; Bak T; Trouillot T; Stolpman N; Everson GT; Kam I
Liver Transpl; 2001 Apr; 7(4):343-51. PubMed ID: 11303295
[TBL] [Abstract][Full Text] [Related]
17. Conversion to tacrolimus extended-release formulation: short-term clinical results.
Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
Boratyńska M; Banasik M; Patrzalek D; Szyber P; Klinger M
Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
[TBL] [Abstract][Full Text] [Related]
20. The long-term outcome of tacrolimus in cadaveric kidney transplantation from non-heart beating donors.
Fukuhara N; Ono Y; Hattori R; Nishiyama N; Yamada S; Kamihira O; Kinukawa T; Ohshima S
Clin Transplant; 2005 Apr; 19(2):153-7. PubMed ID: 15740548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
